Get healthy returns from these three innovative healthcare stocks
Professional investor Michael Li of the American Century Advanced Medical Impact Fund looks at three healthcare stocks
Healthcare is an exciting sector. The incredibly rapid development of effective coronavirus vaccines is just one example of its tremendous potential for innovation and making a positive social impact. We also feel there is scope for healthy returns. Healthcare companies are innovating not just in therapeutics and medical devices, but also in terms of big data and analytics. As a result, we believe we are on the verge of a transformation in how care is delivered and diseases are treated.
Speeding up drug trials
Veeva Systems (NYSE: VEEV) is a cloud-software company whose technology helps plan drug trials safely and effectively. The process of developing a new drug takes over a decade and costs millions of dollars. This use of data analytics and information technology helps reduce approval times and costs, and raises the probability of success.
The company serves over 750 customers, including 20 of the largest pharmaceutical companies. Its technology typically accelerates regulatory submissions by 20%, which is crucial for patients likely to benefit from innovative treatments. Veeva’s platform also accelerates drug development by reducing the start-up time in clinical studies by 40%.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
A cocktail to combat Covid-19
Regeneron Pharmaceuticals (Nasdaq: REGN) is a biotechnology company engaged in the development of medicines for the treatment of serious diseases. It is pouring resources into research and development (R&D) and it maintains one of the world’s most comprehensive genetic databases, with a million people sequenced by the Regeneron Genetics Center. Regeneron is well known today for its Covid-19 antiviral drug cocktail, which has so far proved effective against the various strains of the disease, and is gaining market share from competing therapies. But Regeneron’s research effort goes far beyond Covid-19.
The company has developed and markets drugs addressing several serious medical conditions, including a type of inoperable skin cancer, wet age-related macular degeneration, asthma and eczema among others. Regeneron has approximately 30 potential treatments in clinical development.
Transforming diabetes care
DexCom (Nasdaq: DXCM) is an innovative medical-device company transforming the quality of life and standard of care for diabetics. The company produces a continuous glucose monitoring (CGM) system, which allows patients and care providers to evaluate and adjust care quickly and effectively in real time.
A sensor is placed under the patient’s skin and attached to a tiny transmitter that continuously relays data on blood-sugar levels. The data can be read on a dedicated receiver, displayed on an iPhone, or monitored remotely by a care provider. This technology is transformative: traditional glucose monitoring depends on intermittent, inconvenient and painful finger pricks and self-monitoring.
Not only is DexCom attractive for its positive impact on the lives of diabetics, but the company is also gaining market share, broadening the range of potential applications for its products and expanding geographically.
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
Cash in on the growth prospects of Europe's companies
Opinion Marcel Stötzel, co-portfolio manager of the Fidelity European Trust, selects three stocks
By Marcel Stotzel Published
-
Is the AI boom another dotcom bubble?
25 years on from the dotcom bubble bursting, is it time for investors to consider the sustainability of the AI boom in the stock market?
By Dan McEvoy Published
-
Cash in on the growth prospects of Europe's companies
Opinion Marcel Stötzel, co-portfolio manager of the Fidelity European Trust, selects three stocks
By Marcel Stotzel Published
-
Why CEOs deserve a pay rise
Opinion The CEOs of big companies often come under fire for being grossly overpaid. But the truth, as per some economists, is the opposite. Do they merit a pay rise?
By Stuart Watkins Published
-
Rolls-Royce stock jumps 15% – could it climb further?
Aircraft-engine group Rolls-Royce’s CEO has been hailed as a hero for spearheading the firm’s recovery. And the future looks bright, says Matthew Partridge
By Dr Matthew Partridge Published
-
The power of private markets
Interview Helen Steers, co-manager of the Pantheon International investment trust, tells MoneyWeek about the vast array of compelling opportunities in private equity
By Andrew Van Sickle Published
-
Vertex Pharmaceuticals is an uncommon opportunity in rare diseases
Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success
By Dr Mike Tubbs Published
-
Global investors have overlooked these top tips in emerging markets
Opinion Chris Tennant, co-portfolio manager of Fidelity Emerging Markets, picks three attractive companies in emerging markets
By Chris Tennant Published
-
King Coal has not been dethroned yet — should you buy?
The demand for coal is only growing, yet investors don’t seem to want to take advantage of the opportunity, says Rupert Hargreaves
By Rupert Hargreaves Published
-
It’s time to start buying Europe again, says Merryn Somerset Webb
Opinion Europe's stocks are cheap and the economic backdrop is starting to look cheerier, says Merryn Somerset Webb
By Merryn Somerset Webb Published